CCR2 and neoplasm: We profiled the tumor myeloid cell population on day 3 post-IR for all treatment groups: IgG isotype control, 20 Gy + IgG control, anti-CCR2 antibody, and 20 Gy + anti-CCR2 antibody (Fig. 3d and Supplementary Fig. 1C).